.jpg?format=webp&width=780)
The global surge in kidney disease is intertwined with the alarming rise in obesity, diabetes, and metabolic syndrome (MetS). This cluster of cardiovascular risks, characterized by factors like visceral fat, insulin resistance, and high blood pressure, significantly contributes to chronic kidney issues. Despite therapies like RAAS inhibitors and SGLT-2 inhibitors, the risk of kidney disease progression remains high in obese and diabetic populations. MetS, fostering inflammation and oxidative stress, wreaks havoc on renal function, particularly the highly vascularized kidney.
Like
Save
Share